(Q33620592)

28 July 2017

A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia (English)

1 reference

28 July 2017

0 references

0 references

Daniel Umbricht

1

1 reference

28 July 2017

Richard S E Keefe

2

1 reference

28 July 2017

Stephen Murray

3

1 reference

28 July 2017

David A Lowe

4

1 reference

28 July 2017

Richard Porter

5

1 reference

28 July 2017

George Garibaldi

6

1 reference

28 July 2017

Luca Santarelli

7

1 reference

28 July 2017

language of work or name

English

0 references

publication date

27 January 2014

1 reference

28 July 2017

Neuropsychopharmacology

1 reference

28 July 2017

39

1 reference

28 July 2017

7

1 reference

28 July 2017

1568-1577

1 reference

https://scigraph.springernature.com/pub.10.1038/npp.2014.17

28 July 2017

0 references

cites work

A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Acetylcholinesterase inhibitors for schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Cognitive training in schizophrenia: a neuroscience-based approach

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Initial phase 2 trial of a nicotinic agonist in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Molecular targets for treating cognitive dysfunction in schizophrenia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Size of treatment effects and their importance to clinical research and practice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Neuronal nicotinic receptors: from structure to pathology

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Schizophrenia, sensory gating, and nicotinic receptors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Galantamine for the treatment of cognitive impairments in people with schizophrenia

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.17

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.17

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.17

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.17

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.17

Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.17

N-terminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.17

Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023143

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24549101

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NPP.2014.17

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference